title: Inflammation-associated graft loss in renal transplant recipients.
abstract: BACKGROUND
  Although short-term graft survival has improved substantially in renal transplant recipients, long-term graft survival has not improved over the last decades. The lack of knowledge of specific causes and risk factors has hampered improvements in long-term allograft survival. There is an uncertainty if inflammation is associated with late graft loss.
  
  
  METHODS
  We examined, in a large prospective trial, the inflammation markers high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) and their association with chronic graft dysfunction. We collected data from the Assessment of Lescol in Renal Transplant trial, which recruited 2102 maintenance renal transplant recipients.
  
  
  RESULTS
  Baseline values were hsCRP 3.8 ± 6.7 mg/L and IL-6 2.9 ± 1.9 pg/mL. Adjusted for traditional risk factors, hsCRP and IL-6 were independently associated with death-censored graft loss, the composite end points graft loss or death and doubling of serum creatinine, graft loss or death.
  
  
  CONCLUSIONS
  The inflammation markers hsCRP and IL-6 are associated with long-term graft outcomes in renal transplant recipients.
authors.affiliation: Department of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. d_o_dahle@yahoo.com
authors.forename: Dag Olav
authors.initials: DO
authors.lastname: Dahle
authors.forename: Geir
authors.initials: G
authors.lastname: Mjøen
authors.forename: Björn
authors.initials: B
authors.lastname: Oqvist
authors.forename: Hubert
authors.initials: H
authors.lastname: Scharnagl
authors.forename: Gisela
authors.initials: G
authors.lastname: Weihrauch
authors.forename: Tanja
authors.initials: T
authors.lastname: Grammer
authors.forename: Winfried
authors.initials: W
authors.lastname: März
authors.forename: Sadollah
authors.initials: S
authors.lastname: Abedini
authors.forename: Gudrun E
authors.initials: GE
authors.lastname: Norby
authors.forename: Ingar
authors.initials: I
authors.lastname: Holme
authors.forename: Bengt
authors.initials: B
authors.lastname: Fellström
authors.forename: Alan
authors.initials: A
authors.lastname: Jardine
authors.forename: Hallvard
authors.initials: H
authors.lastname: Holdaas
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism*; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D005260:Female; D000077340:Fluvastatin; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000097:blood* / Q000209:etiology / Q000401:mortality; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood* / Q000209:etiology / Q000401:mortality; D015850:Interleukin-6 / Q000097:blood*; D007674:Kidney Diseases / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D015850:Interleukin-6; D000077340:Fluvastatin; D002097:C-Reactive Protein; D003404:Creatinine